Citi analysts updated their MedTech coverage post-Q1, with rating changes and price adjustments. Despite tariff challenges, the sector's fundamentals remain stable. Citi downgraded BDX, upgraded ITGR, and maintained outlook on COO and BSX. COO's FX performance is anticipated positively.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing